Company Overview
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Why Investors Should Care
Revenue has grown at a 11.6% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.27.
Recent Developments
- Dec 2025 Revenue of $11.16M (+11.7% YoY); net profit $-148.12M.
- Trailing 12 Months Year-on-year growth — revenue -43.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 11.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 11.56% |
| 1 Year: | -43.80% |
Stock Price Performance
| 1 Year: | -21.03% |
| 6 Months: | -21.83% |
| 3 Months: | -16.30% |
| 1 Month: | -6.67% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)42.85 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 11.6% over 5 years.
CONS
- Trading 45.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CRBU Caribou Biosciences, Inc. PHARMA | 1.54 | -1.43 | $165.10M | 0.00% | -98.93% | -78.27% | 11.56% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.70M | 8.48M | 1.20M | 984.00K | 1.59M | 1.48M | 3.98M | 2.56M | 2.66M | 4.19M | 3.30M | 3.50M | 3.75M | 23.66M | 2.43M | 3.46M | 2.02M | 2.35M | 2.67M | 2.20M | 2.40M |
| Operating Income | -10.43M | -2.25M | -8.23M | -15.21M | -13.18M | -15.96M | -18.62M | -20.41M | -20.85M | -28.43M | -26.54M | -31.12M | -32.87M | -14.63M | -46.00M | -43.50M | -38.24M | -42.91M | -47.58M | -29.40M | -26.28M |
| Net Income | -9.80M | -1.87M | -7.93M | -14.70M | -13.16M | -14.31M | -20.97M | -18.48M | -19.09M | -26.70M | -26.65M | -28.04M | -29.52M | -10.00M | -41.23M | -37.70M | -34.68M | -39.99M | -54.10M | -27.55M | -25.09M |
| Diluted EPS | - | - | - | - | - | -1.39 | -0.46 | - | -0.32 | -0.44 | -0.44 | -0.46 | -0.48 | -0.12 | -0.46 | -0.42 | -0.38 | -0.43 | -0.58 | -0.30 | -0.26 |
| R&D Expense | 8.64M | 7.58M | 6.18M | 12.02M | 10.16M | 12.33M | 15.83M | 15.11M | 13.92M | 22.58M | 19.99M | 25.71M | 26.50M | 28.58M | 33.79M | 35.48M | 30.42M | 35.53M | 27.69M | 22.40M | 20.61M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 5.79M | 12.36M | 9.60M | 13.85M | 34.48M | 9.99M | 11.16M |
| Operating Income | -34.30M | -36.12M | -66.98M | -106.40M | -116.06M | -166.62M | -148.34M |
| Net Income | -23.43M | -34.31M | -66.92M | -99.42M | -102.07M | -149.10M | -148.12M |
| Diluted EPS | - | - | -2.11 | -1.64 | -1.38 | -1.65 | -1.59 |
| R&D Expense | 23.64M | 34.42M | 52.26M | 82.23M | 112.08M | 130.15M | 109.44M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 36.05M | 442.36M | 373.76M | 432.21M | 313.31M | 175.37M |
| Total Equity | 29.95M | 7.46M | -23.44M | 387.82M | 300.87M | 368.40M | 252.95M | 122.17M |
| Cash & Equivalents | - | 41.07M | 15.95M | 240.42M | 58.34M | 51.16M | 16.29M | 12.36M |
| Total Liabilities | - | - | 18.16M | 54.53M | 72.89M | 63.81M | 60.36M | 53.19M |
| Current Liabilities | - | - | 12.39M | 25.83M | 28.13M | 28.30M | 30.65M | 25.41M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -32.01M | -33.22M | -32.52M | -90.97M | -93.29M | -138.20M | -110.99M |
| Investing Cash Flow | 27.23M | 6.36M | -176.40M | -93.25M | -68.18M | 86.61M | 102.24M |
| Financing Cash Flow | 172.00K | 1.74M | 433.43M | 2.13M | 154.30M | 16.72M | 4.82M |
| Capital Expenditure | -884.00K | -317.00K | -2.12M | -6.45M | -11.61M | -4.88M | -1.36M |
| Free Cash Flow | -32.89M | -33.53M | -34.64M | -97.42M | -104.90M | -143.08M | -112.35M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | -592.7% | -292.2% | -697.8% | -768.2% | -336.6% | -1,667.2% | -1,329.4% |
| Net Margin % | -404.8% | -277.6% | -697.3% | -717.8% | -296.1% | -1,491.9% | -1,327.4% |
| ROE % | -314.0% | 146.4% | -17.3% | -33.0% | -27.7% | -58.9% | -121.2% |
| ROCE % | - | -152.7% | -16.1% | -30.8% | -28.7% | -58.9% | -98.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.29% | 7.82M | $10.16M |
| 2 | Pfizer Inc | 4.38% | 4.69M | $6.10M |
| 3 | Vanguard Capital Management LLC | 3.93% | 4.21M | $5.47M |
| 4 | Mackenzie Financial Corporation | 3.41% | 3.65M | $4.75M |
| 5 | Renaissance Technologies, LLC | 2.59% | 2.77M | $3.61M |
| 6 | Kynam Capital Management, LP | 2.34% | 2.50M | $3.25M |
| 7 | Geode Capital Management, LLC | 2.22% | 2.37M | $3.09M |
| 8 | Acadian Asset Management. LLC | 1.66% | 1.77M | $2.31M |
| 9 | State Street Corporation | 1.52% | 1.63M | $2.12M |
| 10 | Bank of America Corporation | 1.32% | 1.41M | $1.83M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CRBU
Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxONXJDUllyVkQ0RlBmRGhJVGtWWl9wbGZvRVhkV2RJbTRBN1l3M2hFNVhyamhhLW9KN1dFX0ktY2JlTzhHS1FOWkp3OUJCVDY2U0VoSU1uTEdlbTZZUnF0WWlsbzRzaUh6RENGMkNwa0dha1JJeENwb0xycEhzdWZ1eDBicDQ2WnBuTVF3ZF…
CRBU Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9jdHgzVXBfSjVzUWRuNUhRN1U4TDNOX0NRT0REdk1kRzFLc3hlcnpNbWQyMWNkVXcycVFzVjV4UGdoZmZOSVdNdk8wTlRxc2VxdzBjS1lpajhXbHJQM3pwQlNfTW8wZ0NILUUtZ1NBUF9RSWs1NVVYUnln?oc=5" target="_blank">CRB…
Caribou's Single-Dose CAR-T Shows 92% Response in 12 Myeloma Patients - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxObVNwWVhvaURhWUVjNFZSdkFEN1dDbnNtZVllMDNJYWxQc3MwUFROVmljQmQ2bVAwTVBTUUxOYjhfaUU1MUEyZjBkWUVOUWtOU3BuOUVuMHpBYlVPeGNoajZlS01IX2tXemdMNFE0dmRzTFlIZzFPeF82LXpYN1FjV3NtR0NET0ZJeGNlRl…
$CRBU stock is down 14% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQM1d4NXZNR2NmT01vMXJYekRIYXl1QnZaS21obXpid3pDSHQ1VVp0Znl0YkJEWjNjVWY0TVVRVVNuNHJoVTNqeE1wWnBYOGRtM0Rsc2xjQlhxOUV2WWItaklKdHlxdXRDSXZ5NnNyUkFtWjlsMzZscGZnc1h6UHUtdVJvNzlGRzM4bFVaNE…
CRBU - Caribou Biosciences Inc Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE0tbm5SVTNvUEN5UkFiVmJiUjh5U2QwbWl3cHF1bGNiZUNTemlDUE02elhyaE11SUM5YzltN3N0c2x4VzB1WEE?oc=5" target="_blank">CRBU - Caribou Biosciences Inc Stock Price and Quote</a> <fon…
H.C. Wainwright reiterates Caribou Biosciences stock rating at buy - Investing.com
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxONTk2b2hkMm9xY0p4dmw5eXU4T2dsVi11d2hVVWlnTkNlaTk2Nm1LQktORlIzaDlUYU9hUFA0ZUROajBrTUl1S0NMYUtxeVQ5anFFVFUtbDlNUm5iZ1kxbnQ4YW1fcTk3blNrSWt2QUthaFlkdkdsTW1SLS1wQ0FlTnA3NWNYbHlPbVR5NH…
CRBU — Frequently Asked Questions
What is the current share price of Caribou Biosciences, Inc. (CRBU)?
As of 2026-09-19 21:16 PDT, Caribou Biosciences, Inc. (CRBU) trades at $1.54 on NasdaqGS. Its 52-week range is $1.39 to $2.84.
What is the market capitalisation of CRBU?
Caribou Biosciences, Inc. (CRBU) has a market capitalisation of $165.10M on NasdaqGS.
What is the P/E ratio of CRBU?
CRBU trades at a trailing price-to-earnings (P/E) ratio of -1.43. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.56.
What is the return on equity (ROE) of CRBU?
CRBU has a return on equity (ROE) of -78.27%. Its return on capital employed (ROCE) is -98.93%.
Is CRBU a good stock to buy?
This page provides a data-driven analysis of Caribou Biosciences, Inc. (CRBU), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.